Pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration ( FDA) approved betamethasone dipropionate ointment USP (Augmented), 0.05%. The product would be manufactured at Lupin’s Pithampur (Unit III) facility, India.
Betamethasone dipropionate ointment USP (Augmented), 0.05%, is the generic equivalent of Diprolene ointment, 0.05%, of Merck Sharp and Dohme Corp. It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.
Betamethasone dipropionate ointment USP (Augmented), 0.05%, (Diprolene) had an annual sales of approximately USD 21 million in the US (IQVIA MAT January 2020).
Also read: USFDA Approves Coronavirus Test: Detection Time: 45 Min
